Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Abnormal 3-D MRI Flow Patterns in Adolescents Patients With Bicuspid Aortic Valve
This study is currently recruiting participants.
Verified by Emory University, September 2008
Sponsors and Collaborators: Emory University
Children's Healthcare of Atlanta
Information provided by: Emory University
ClinicalTrials.gov Identifier: NCT00412386
  Purpose

Bicuspid aortic valve (BAV) is a form of congenital heart disease (the person is born with it). With BAV, the heart valves in the aorta (the blood vessel that takes blood away from the heart to the body) are not formed right. A person with BAV has only 2 leaflets instead of three and the valve leaflets are often thickened. This can result in the block of blood flow across the valve (aortic stenosis) and/or valve leakage (aortic valve regurgitation).

From our experience at least 1/3 of patients with BAV will eventually develop complications. Many patients with BAV do not develop significant problems until well into adulthood. The most common problem in BAV patients is aortic dilatation and/or dissection. At this point, we do not know on who or why aortic dilatation or dissection occurs.It is unclear whether the enlargement is because of abnormal blood flow patterns, as a result of the shape of the bicuspid valve, or whether it is because the way the aortic valve and/or vessel is formed. In other words, the abnormal shape of the aortic valve may cause blood to flow in a different way than it normally would, causing damage to the aorta as blood leaves the heart. There may be a problem with the way the aortic valve connects to the aorta, which causes the aorta to get larger or break down over time. It is also possible that the wall of the aorta in patients with BAV is weaker than it would be in patients without BAV. At this point, we do not know. It is believed by the investigators that if we can determine why the aorta gets larger or tears, we can minimize the effects or prevent them altogether.

This study will collect blood and cardiac MRI images from forty-five (45) patients at Children's Healthcare of Atlanta Egleston. There will be a study group (patients with BAV) and a control group of patients (patients scheduled for a cardiac MRI but without BAV).

All enrolled patients will have blood drawn by nursing staff from a peripheral vein and collected in tubes for testing the day of their MRI scan. This test is called a plasma matrix metalloproteinase level. It is believed that patients who have bicuspid aortic valves and dilated aortas have high plasma levels of this protein. This study will compare the MRI images and plasma matrix protein levels of all the patients participating in the study.


Condition Intervention
Congenital Heart Disease
Bicuspid Aortic Valve
Procedure: Cardiac MRI (magnetic resonance image)
Procedure: plasma matrix metalloproteinase level

MedlinePlus related topics: Heart Diseases
U.S. FDA Resources
Study Type: Observational
Study Design: Case Control, Prospective
Official Title: Abnormal 3-Dimensional MRI Flow Patterns and Plasma Matrix Metalloproteinase Levels Predict Dilatation of Ascending Aorta in Adolescent Patients With Bicuspid Aortic Valve

Further study details as provided by Emory University:

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 45
Study Start Date: December 2006
Intervention Details:
    Procedure: Cardiac MRI (magnetic resonance image)
    MRI of the heart
    Procedure: plasma matrix metalloproteinase level
    lab draw
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   10 Years to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

patients with bicuspid Aortic valve, normal healthy volunteers, and congential heart disease without bicuspid aortic valve

Criteria

Inclusion Criteria:

  • diagnosed with Bicuspid Aortic Valve 15 with aortic root dilatation 15 without aortic root dilatation
  • 15 patients with congenital heart disease, but not bicuspid aortic valve
  • meet eligibility criteria for MRI
  • 10-18 years of age

Exclusion Criteria:

  • under 10 years and over 19 years of age
  • systemic hypertension for age and height
  • Marfan syndrome
  • on cardiac or vasoactive medications
  • contra-indications to MRI such as metallic implants
  • acquired heart disease
  • require sedation
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00412386

Contacts
Contact: Denver Sallee, MD 404-785-1290 salleed@kidsheart.com
Contact: Jeryl Huckaby, RRT, CCRC 404-785-0422 jeryl.huckaby@choa.org

Locations
United States, Georgia
Childrens Healthcare of Atlanta Recruiting
Atlanta, Georgia, United States, 30322
Principal Investigator: Denver Sallee, MD            
Sub-Investigator: Marijn Brummer, PhD            
Sub-Investigator: James Parks, MD            
Sponsors and Collaborators
Emory University
Children's Healthcare of Atlanta
Investigators
Principal Investigator: Denver Sallee, MD Emory University
  More Information

Publications:
Responsible Party: Emory University ( Emory University IRB Chairman )
Study ID Numbers: 134
Study First Received: December 14, 2006
Last Updated: September 10, 2008
ClinicalTrials.gov Identifier: NCT00412386  
Health Authority: United States: Institutional Review Board

Keywords provided by Emory University:
Pediatric
Congenital Heart Disease
Imaging

Study placed in the following topic categories:
Heart Diseases
Cardiovascular Abnormalities
Dilatation, Pathologic
Congenital Abnormalities
Heart Defects, Congenital

Additional relevant MeSH terms:
Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009